This book is the first to focus on Bayesian phase I-II clinical trials. It describes many problems with the conventional phase I-phase II paradigm and covers a large number of modern Bayesian phase I-II clinical trial designs.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Ying Yuan is a professor and co-chief of the Section of Adaptive Clinical Trials in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct associate professor in the Department of Statistics at Rice University. Dr. Yuan has published over 100 peer-reviewed research papers in top statistical and medical journals. He is an associate editor of Biometrics and a board member of the International Chinese Statistical Association. He received his PhD in biostatistics from the University of Michigan. His research interests include Bayesian adaptive clinical trial design, statistical analysis of missing data, and Bayesian statistics.
Hoang Q. Nguyen is a senior computational scientist in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He received his PhD in computational and applied mathematics from Rice University. His research interests include Bayesian clinical trial design, computational algorithms, regression modeling, and Bayesian data analysis.
Peter F. Thall is the Anise J. Sorrell Professor in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct professor in the Department of Statistics at Rice University. Dr. Thall is a fellow of the American Statistical Association (ASA) and the Society for Clinical Trials, an associate editor for Clinical Trials and Statistics in Biosciences, and an ASA Media Expert. He has published over 200 papers and book chapters in the statistical and medical literature. He received his PhD in statistics and probability from the Florida State University. His research interests include clinical trial design, dynamic treatment regimes, prior elicitation, Bayesian nonparametric statistics, and personalized medicine.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Gratis für den Versand innerhalb von/der USA
Versandziele, Kosten & DauerEUR 17,64 für den Versand von Vereinigtes Königreich nach USA
Versandziele, Kosten & DauerAnbieter: ThriftBooks-Atlanta, AUSTELL, GA, USA
Hardcover. Zustand: As New. No Jacket. Pages are clean and are not marred by notes or folds of any kind. ~ ThriftBooks: Read More, Spend Less 1.35. Bestandsnummer des Verkäufers G1498709559I2N00
Anzahl: 1 verfügbar
Anbieter: Chiron Media, Wallingford, Vereinigtes Königreich
Hardcover. Zustand: New. Bestandsnummer des Verkäufers 6666-TNFPD-9781498709552
Anzahl: 5 verfügbar
Anbieter: Lucky's Textbooks, Dallas, TX, USA
Zustand: New. Bestandsnummer des Verkäufers ABLIING23Mar2716030242236
Anzahl: Mehr als 20 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: New. Bestandsnummer des Verkäufers 25729671-n
Anzahl: Mehr als 20 verfügbar
Anbieter: Books Puddle, New York, NY, USA
Zustand: New. Bestandsnummer des Verkäufers 26375622493
Anzahl: 4 verfügbar
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Zustand: New. Bestandsnummer des Verkäufers 370422914
Anzahl: 3 verfügbar
Anbieter: California Books, Miami, FL, USA
Zustand: New. Bestandsnummer des Verkäufers I-9781498709552
Anzahl: Mehr als 20 verfügbar
Anbieter: THE SAINT BOOKSTORE, Southport, Vereinigtes Königreich
Hardback. Zustand: New. New copy - Usually dispatched within 4 working days. 652. Bestandsnummer des Verkäufers B9781498709552
Anzahl: 1 verfügbar
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity. 324 pp. Englisch. Bestandsnummer des Verkäufers 9781498709552
Anzahl: 2 verfügbar
Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New. PRINT ON DEMAND. Bestandsnummer des Verkäufers 18375622487
Anzahl: 4 verfügbar